Poster

Analysis of Pre-Exposure Prophylaxis Utilization in a Medicaid Population

Commonwealth Medicine is now ForHealth Consulting at UMass Chan Medical School. More information available here. This content has not been updated with the new name.

Approximately two million new cases of human immunodeficiency virus (HIV) infection occur every year. Adhering to a pre-exposure prophylaxis therapy(PrEP) allows patients to reduce their risk of transmission by about 90%, but adherence to the therapy can vary a great deal. This presentation evaluates the utilization of two PrEP therapies, emtricitabine/tenofovir disoproxil fumarate (Truvada®) and emtricitabine/tenofovir alafenamide (Descovy®), among a MassHealth population.

Analysis of Pre-Exposure Prophylaxis Utilization in a Medicaid Population